Latest California Healthline Stories
KFF Health News' 'What the Health?': The State of the Union Is … Busy
At last, Congress is getting half of its annual spending bills across the finish line, albeit five months after the start of the fiscal year. Meanwhile, President Joe Biden delivers his annual State of the Union address, an over-the-counter birth control pill is (finally) available, and controversy erupts over new public health guidelines for covid-19 isolation. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Neera Tanden, the White House domestic policy adviser, about Biden’s health agenda. Plus, for “extra credit,” the panelists suggest health policy stories they read this week that they think you should read, too.
How a Friend’s Death Turned Colorado Teens Into Anti-Overdose Activists
High school students in Colorado are pushing for a change they say is necessary to combat fentanyl poisoning: ensuring students can’t get in trouble for carrying the overdose reversal drug naloxone wherever they go, including at school.
Los amigos de un joven muerto por envenenamiento por fentanilo impulsan una ley estatal para que estudiantes de secundaria puedan llevar Narcan en sus mochilas sin riesgo de ser castigados.
An Arm and a Leg: Wait, Is Insulin Cheaper Now?
Did the price of insulin go down? It’s not quite that simple. On this episode of “An Arm and a Leg,” producer Emily Pisacreta explores recent changes to the cost of the diabetes medication.
Patients See First Savings From Biden’s Drug Price Push, as Pharma Lines Up Its Lawyers
A restructuring of the Medicare drug benefit has wiped out big drug bills for people who need expensive medicines. But the legal battle over drug negotiations means uncertainty over long-term savings.
KFF Health News' 'What the Health?': Biden Wins Early Court Test for Medicare Drug Negotiations
A federal district court judge dismissed a lawsuit attempting to invalidate the Biden administration’s Medicare prescription-drug price negotiation program. But the suit turned on a technicality, and several more court challenges are in the pipeline. Meanwhile, health policy pops up in Super Bowl ads, as Congress approaches yet another funding deadline. Alice Miranda Ollstein of Politico, Lauren Weber of The Washington Post, and Rachel Cohrs of Stat join KFF Health News’ Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
KFF Health News' 'What the Health?': The Struggle Over Who Gets the Last Word
As science skepticism pervades politics, the Supreme Court will soon consider two cases that seek to define the power of “experts.” Meanwhile, abortion opponents are laying out plans for how Donald Trump, if reelected as president, could effectively curtail abortion even in states where it remains legal. Sandhya Raman of CQ Roll Call, Joanne Kenen of Johns Hopkins University and Politico Magazine, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Samantha Liss, who reported and wrote the latest KFF Health News-NPR “Bill of the Month” feature about a husband and wife who got billed for preventive care that should have been fully covered.
Surge in Syphilis Cases Leads Some Providers to Ration Penicillin
Injectable penicillin is the go-to treatment for syphilis and the only treatment considered safe for pregnant people with the disease. But as rates of syphilis increase across the U.S., a shortage of the injectable has prompted some public health agencies to ration it.
Médicos deben racionar la penicilina por el dramático aumento de casos de sífilis
A nivel nacional, las tasas de sífilis están en su punto más alto en 70 años. Entre 2018 y 2022, las tasas de esta enfermedad de transmisión sexual subieron alrededor del 80%.
The FTC Is Attacking Drugmakers’ ‘Patent Thickets’
It’s a big job clearing out so-called “patent thickets” drugmakers create to keep their products’ prices high. But the Federal Trade Commission is giving it a shot.